About Recurrent Vulvovaginal Candidiasis (RVVC)

Recurrent vulvovaginal candidiasis (RVVC) is a debilitating, chronic infectious condition that affects millions of women. Primary symptoms include vaginal itching, burning, irritation and inflammation. Some women may experience abnormal vaginal discharge and painful sexual intercourse or urination, causing variable but often severe discomfort and pain.

Although the physical symptoms can be distressing, often the emotional and psychological consequences of the recurrent infections affect sufferers most. RVVC impacts quality of life, to a degree comparable to asthma and worse than diseases such as headache and migraine, yet despite the high prevalence, there are currently no agents in the United States approved to treat the condition.

For some patients with RVVC, chronic treatment with fluconazole given once-weekly may be used. However, there is significant concern regarding the chronic use of fluconazole in women of child-bearing age as a result of the drug’s Category D pregnancy warning and other safety issues. 

Mycovia is developing oral VT-1161 for the treatment of RVVC. This investigational agent has successfully completed a Phase 2b clinical study in patients diagnosed with RVVC. VT-1161 has the potential to be a safe and effective oral treatment for RVVC.

Click here to learn more about the clinical trial of VT-1161 in RVVC and other important indications.

 

About Onychomycosis

A fungal infection that involves the nail as well as the skin under and around the nail, onychomycosis affects approximately 35 million individuals in the United States and millions more around the globe. The prevalence of onychomycosis increases with age, with approximately 18% of individuals over the age of 60 affected. The infection typically involves one or more toenails, although fingernail infections represent about 5% of cases.  

Onychomycosis is a chronic condition, often developing over a period of months or even years. The infected nail can become discolored, thickened and disfigured, and may result in pain when walking. Onychomycosis can also be a significant medical issue for diabetics or other patients with compromised immune systems. In these patients, the infected nail can serve as an entry point for bacterial infection, which can lead to serious complications such as amputation. 

Onychomycosis will rarely improve without medical treatment. Due to concerns about possible side effects, limited efficacy and frequent relapse experienced with current therapies, physicians may discourage some patients from undergoing currently available treatments, which include both oral and topical therapies.

Mycovia is developing oral VT-1161 for the treatment of onychomycosis. This investigational agent has successfully completed a Phase 2b clinical study in patients diagnosed with onychomycosis of the large toenail. VT-1161 has the potential to be a safe and effective oral treatment for onychomycosis.